This study provides a medication called DFMO to patients with certain rare and difficult-to-treat childhood cancers. It is designed to offer access to this treatment when standard options have not worked or are no longer available.
This trial is for newborns up to 30 years old who were diagnosed with specific rare cancers like neuroblastoma or medulloblastoma. Participants must meet certain health and size requirements and cannot be in another experimental drug trial.
Participants will receive the study medication, eflornithine HCl, to help manage their condition. Your doctor will closely monitor your health and progress throughout the treatment process.
This study is currently available and taking participants. The location for this study is in Hershey, Pennsylvania, in the United States.
- 1Provides access to the medication DFMO for specific rare childhood cancers.
- 2Open to patients ranging from newborns to 30 years old.
- 3Currently available at a location in Hershey, Pennsylvania.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.